Completed PHASE1 INTERVENTIONAL 1-arm NCT00807872

Radioimmunoimaging of AL Amyloidosis

Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4

Sponsor: FDA Office of Orphan Products Development

Conditions Primary Amyloidosis

Interventions 124I-labeled monoclonal antibody Mu 11-1F4

Updated 6 times since 2017 Last updated: Sep 17, 2013 Started: Dec 31, 2008 Primary completion: Mar 31, 2012 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00807872, this PHASE1 trial focuses on Primary Amyloidosis and remains completed. Sponsored by FDA Office of Orphan Products Development, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FDA Office of Orphan Products Development
University of Tennessee

Data source: University of Tennessee

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Knoxville, United States